Earnings Feed
Start Free
ANAPTYSBIO, INC·4

Apr 22, 6:35 PM ET

Orwin John A 4

4 · ANAPTYSBIO, INC · Filed Apr 22, 2026

Research Summary

AI-generated summary of this filing

Updated

AnaptysBio (ANAB) Director John A. Orwin Receives Adjusted Options

What Happened On April 20, 2026, AnaptysBio director John A. Orwin reported a series of derivative transactions that reflect an adjustment of outstanding options related to a separation/spin-off. The filing shows matched dispositions to the issuer and simultaneous grants/acquisitions of options (all at $0) in amounts of 3,311; 10,600; 16,510; 16,510; and 8,250 — an aggregate of 55,181 option-equivalent shares. These were non-cash adjustments (price $0) tied to the company’s Separation and Distribution Agreement and do not represent open-market purchases or sales.

Key Details

  • Transaction date: April 20, 2026. Form 4 filed April 22, 2026 (appears timely).
  • Transaction types: Multiple dispositions to issuer (D) and grants/acquisitions (A) of derivative interests; all at $0 (non-cash).
  • Aggregate adjusted options reported: 55,181 option-equivalent shares (sum of all A entries).
  • Shares/ownership after transaction: Not specified in the Form 4 provided.
  • Notable footnotes:
    • F1: Adjustments were made pro rata under the Separation and Distribution Agreement; each option was split/adjusted into options to acquire shares of both First Tracks and AnaptysBio.
    • F2: One option reported is fully vested and exercisable.
    • F3: Another option vests 1/12 monthly beginning Feb 6, 2026, subject to continued service.
  • No cash proceeds or open-market trades were reported — this is an administrative/options adjustment, not a sale or purchase.

Context This filing documents a derivative adjustment tied to a corporate separation (spin-off) that altered option allocations between AnaptysBio and the new/related company (First Tracks). For retail investors: these kinds of filings often reflect contractual adjustments rather than insider sentiment. Because no shares were sold on the open market and no cash changed hands, this is not a direct buy/sell signal; it notifies investors of a change in the insider’s option holdings and vesting status.

Insider Transaction Report

Form 4
Period: 2026-04-20
ANAPTYSBIO, INCANAB
Orwin John A
Director
Transactions
  • Disposition to Issuer

    Stock Option (right to buy)

    [F1][F2]
    2026-04-20−3,311→ 3,311 total
    Exercise: $19.50Exp: 2033-09-14→ Common Stock (3,311 underlying)
  • Award

    Stock Option (right to buy)

    [F1][F2]
    2026-04-20+3,311→ 3,311 total
    Exercise: $14.29Exp: 2033-09-14→ Common Stock (3,311 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    [F1][F2]
    2026-04-20−10,600→ 10,600 total
    Exercise: $19.50Exp: 2033-09-14→ Common Stock (10,600 underlying)
  • Award

    Stock Option (right to buy)

    [F1][F2]
    2026-04-20+10,600→ 10,600 total
    Exercise: $14.29Exp: 2033-09-14→ Common Stock (10,600 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    [F1][F2]
    2026-04-20−16,510→ 16,510 total
    Exercise: $21.19Exp: 2034-01-02→ Common Stock (16,510 underlying)
  • Award

    Stock Option (right to buy)

    [F1][F2]
    2026-04-20+16,510→ 16,510 total
    Exercise: $15.53Exp: 2034-01-02→ Common Stock (16,510 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    [F1][F2]
    2026-04-20−16,510→ 16,510 total
    Exercise: $14.83Exp: 2035-01-06→ Common Stock (16,510 underlying)
  • Award

    Stock Option (right to buy)

    [F1][F2]
    2026-04-20+16,510→ 16,510 total
    Exercise: $10.87Exp: 2035-01-06→ Common Stock (16,510 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    [F1][F3]
    2026-04-20−8,250→ 8,250 total
    Exercise: $43.91Exp: 2035-01-06→ Common Stock (8,250 underlying)
  • Award

    Stock Option (right to buy)

    [F1][F3]
    2026-04-20+8,250→ 8,250 total
    Exercise: $32.17Exp: 2036-01-06→ Common Stock (8,250 underlying)
Footnotes (3)
  • [F1]Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement.
  • [F2]The stock option is fully vested and exercisable.
  • [F3]The stock option vests as to 1/12 of the total shares monthly commencing on February 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Signature
/s/ Dan Faga, Attorney-in-Fact|2026-04-22

Documents

1 file
  • 4
    form4-04222026_100442.xmlPrimary